Effects of Current Therapies on Disease Progression in Fabry Disease: A Narrative Review for Better Patient Management in Clinical Practice
Authors:
Open Access
- 5 December 2024
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (2) , 597-635
Abstract
Fabry disease (FD) is a rare lysosomal storage disorder that is characterized by renal, neurological, and cardiovascular dysfunction. Four treatments are currently available for patients with FD; three enzyme replacement therapies (ERTs; agalsidase alfa, agalsidase beta, and pegunigalsidase alfa) and one pharmacological chaperone (migalastat). This review focuses on the evidence for the benefits of ERTs and migalastat, and provides an overview of their impact on disease manifestations and quality of life (QoL). Agalsidase beta is associated with renal, neurological, and cardiovascular benefits, and may prevent renal disease progression. Agalsidase alfa provides stabilizing effects across all main organ systems, although minor sex-specific differences exist in patients with more advanced baseline disease. The benefits of agalsidase alfa and agalsidase beta are similar but depend on the extent of baseline disease. Some data indicate that agalsidase beta may be preferable over the longer term. Both agalsidase alfa and agalsidase beta are associated with improved gastrointestinal and pain symptoms, as well as improved QoL. Patients with advanced end-organ damage tend not to respond as optimally to ERTs as those who initiate ERTs before irreversible organ fibrosis develops, highlighting the need for early treatment initiation. Migalastat, which is only approved for patients with amenable missense gene variants, generally stabilizes renal parameters and provides cardiovascular benefits. Migalastat also improves diarrhea and pain, and stabilizes QoL (although ERT may be more effective for pain management), but the neurological effects of migalastat have not been studied. Real-world data raise concerns about effective in vivo amenability of some genetic variants. Future studies with direct treatment comparisons in patients with FD are needed.Keywords
Funding Information
- Sanofi Italia
This publication has 98 references indexed in Scilit:
- An Expert Consensus Document on the Management of Cardiovascular Manifestations of Fabry DiseaseEuropean Journal of Heart Failure, 2020
- Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)Clinical Pharmacology & Therapeutics, 2020
- Cardiomyopathy and Kidney Function in Agalsidase Beta-Treated Female Fabry Patients: A Pre-Treatment vs. Post-Treatment AnalysisESC Heart Failure, 2020
- Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT studyClinical and Experimental Nephrology, 2019
- Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 YearClinical Pharmacology & Therapeutics, 2018
- Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry2017
- Early Cardiac Changes in Children with Anderson–Fabry Disease2013
- Effects of Switching from Agalsidase Beta to Agalsidase Alfa in 10 Patients with Anderson-Fabry Disease2012
- Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry RegistryJournal of Inherited Metabolic Disease, 2007
- The effect of 12‐month enzyme replacement therapy on myocardial perfusion in patients with Fabry diseaseJournal of Inherited Metabolic Disease, 2006